FDA officials open the door to new psychedelic trial designs

Four officials from the FDA’s Center for Drug Evaluation and Research published a Special Report in the New England Journal of Medicine on 10 September 2026 describing where the agency is willing to bend the standard rules for psychedelic drug trials. The authors are CDER director Michael Davis, Teresa Buracchio of the Office of Neuroscience, and Tiffany Farchione and Bernard Fischer of the psychiatry division.

The problem they address is blinding. A participant given psilocybin or MDMA generally knows, and so does the rater; an inert placebo does not conceal a drug whose effects are, in the officials’ framing, pronounced and recognisable. Broken blinding contaminates the subjective rating scales that psychiatric trials depend on. The report says sponsors may instead use an active comparator, or a low dose of the same drug, as the control arm.

The second flexibility concerns duration. Rather than resolving up front how often a drug should be given, the agency would consider approval on efficacy measured over a clinically meaningful window — the report gives twelve weeks as the example — with longer-term safety collected afterwards. Risk-management tools, including a REMS with elements to assure safe use, may be attached.

This is a statement of regulatory thinking by named officials, not a guidance document or a rule. It follows the agency’s final psychedelic clinical-trial guidance issued in July 2026.